National Pharmaceutical Pricing Authority (NPPA) has reportedly imposed a penalty of around Rs 300 crore on Novartis for over pricing its popular painkilling medicine Voveran. The company has also received a show cause notice to explain in two weeks why action should not be taken against it for overcharging.
Novartis India is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare.
| Company Name | CMP |
|---|---|
| Redington | 220.95 |
| Adani Enterprises | 2088.20 |
| Amrapali Industries | 17.32 |
| Rashi Peripheral | 404.30 |
| PDS | 295.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: